3 Recruiting Recurrent Lung Non-Small Cell Carcinoma Phase 3 Clinical Trials
Active phase 3 studies for recurrent lung non-small cell carcinoma enrolling across the USA. Verify eligibility and contact site coordinators.
All Recurrent Lung Non-Small Cell Carcinoma studiesPhase 3 Studies for Recurrent Lung Non-Small Cell Carcinoma
🔵 Active, Not Recruiting Phase3
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska
View Study & Checklist ➔ 🟢 Recruiting Phase2 / Phase3
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
📍 Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis — Daphne, Alabama
View Study & Checklist ➔